Non-Small Cell Lung Cancer Analysis

EMA backs datopotamab deruxtecan, but lung cancer access remains unclear

EMA · lung cancer · 9 min

EMA backs datopotamab deruxtecan for advanced lung cancer

EMA · lung cancer · 10 min

Lenacapavir PrEP shows high HIV-prevention efficacy in Gilead’s Phase 3 trials

oncology · 7 min

Vertex launches Journavx after FDA approval for acute pain

FDA · oncology · 9 min

AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint

oncology · 8 min

Listeria Outbreaks 2026: FDA and CDC Soft Cheese Recall Analysis for Pharma

FDA · oncology · 6 min

5 Notable Oncology FDA Approvals Granted in May: A B2B Analysis

FDA · oncology · 6 min

FDA clears U.S. trial of MAIA lung cancer drug for third-line patients

FDA · lung cancer · 6 min

Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?

FDA · non-small cell lung cancer · 5 min

Roche's Alecensa Secures Expanded Approval in Japan for ALK-Positive Lung Cancer

FDA · ALK Tumors · 9 min

Osimertinib FDA Approval Expands Early-Stage NSCLC Treatment

FDA · early-stage non-small cell lung cancer (NSCLC) adjuvant therapy · 6 min

KRAS G12C Inhibitors NSCLC: Market Analysis of Sotorasib & Adagrasib

FDA · oncology · 9 min